Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.
about
Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapyMammalian target of rapamycin inhibitors for heart transplant patientsmTOR inhibitors in advanced renal cell carcinomaNext-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V)Mammalian target of rapamycin inhibitors for heart transplant patientsImmunosuppressive potency of mechanistic target of rapamycin inhibitors in solid-organ transplantationDrug Eluting Stents for Malignant Airway Obstruction: A Critical Review of the LiteratureEverolimus-eluting stent platforms in percutaneous coronary intervention: comparative effectiveness and outcomesDo wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trialsNon-viral infections in children after renal transplantationTargeting the intragraft microenvironment and the development of chronic allograft rejectionMHC class I signaling: new functional perspectives for an old moleculeCardiac allograft vasculopathy: diagnosis, therapy, and prognosis.Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapyImmune-mediated vascular injury and dysfunction in transplant arteriosclerosisManagement of allosensitized cardiac transplant candidatesOral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels.Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data.Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction.Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy.Sirolimus therapy following early cyclosporine withdrawal in transplant patients: mechanisms of action and clinical results.The pros and the cons of mTOR inhibitors in kidney transplantation.The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation.[Biomarker for diagnosis of rejection after heart transplantation].Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumorsSurgical biology for the clinician: vascular effects of immunosuppressionCo-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.Immunoregulatory functions of mTOR inhibition.Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial.Cardiac allograft vasculopathy: current knowledge and future direction.Multiple indications for everolimus after liver transplantation in current clinical practice.Coronary microvasculopathy in heart transplantation: Consequences and therapeutic implications.Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors.Immunosuppression for lung transplantation.The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease.Pediatric heart transplantation-indications and outcomes in the current era.Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling.Steroid-free and steroid withdrawal protocols in heart transplantation: the review of literature.Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part IImmunological advantages of everolimus versus cyclosporin A in liver-transplanted recipients, as revealed by polychromatic flow cytometry.
P2860
Q21198871-87B7ACC6-F68D-4480-90BB-A0364E611E57Q24194002-CDD4A4C1-98A2-446D-84E9-1624B562B522Q24612127-4E064222-B01F-4381-B969-506C3A765F08Q24642679-A2FAFA40-B334-436B-9670-4806197261B8Q26470671-89F2F708-0348-4478-A95E-2979FE0B3BECQ26751433-D7E408FE-101E-4BFF-9AF1-99FDD5DE0062Q26766244-98D37BE7-2D6D-4B17-AA8F-D88AAA099DE1Q26798582-E1843B2E-2967-49DC-B50F-8E16F97535C4Q26823281-5D49C2A9-48E0-4EA7-8A1A-F073EBEA279BQ26825208-F65BB15E-E4A7-406F-A3B4-045706B94C69Q26852762-EB4B5B20-26DD-4285-BD20-9089B9F4DAE4Q27000194-EE31F427-843B-4BE7-A494-9B741F056589Q27011330-9A5F3130-E28C-44B1-970A-CEB582E75947Q28079861-2EEE443E-4AF4-4174-BCCA-8FC3EBD74403Q28084366-234A5FD6-EAE3-4B83-B5DE-D29DA45B09CCQ28749508-C5ABD88C-D6C1-4C95-B5CC-B51948D27584Q30482901-B51ECA2C-774D-4C1D-8D4F-160FB860660EQ30983921-56076F0A-9A3C-4302-AF10-A2D050E69213Q31108592-299EFB3C-408B-454B-B32D-60DDF9966B8FQ33242978-C63B5545-F336-4724-970A-F250FA484BCBQ33376348-C1068D6A-7191-4D87-8608-928AB42C8713Q33412367-ED0CDEA5-27D6-4ABA-8BB8-6BFE5B31F0BAQ33521351-1424E667-D151-4DF9-88E6-BF26917C0E5CQ33530170-DA90D034-B625-45A1-B794-8229FB45574EQ33566872-FB3CA5DE-785C-4405-8F85-08511CCFABC9Q33604754-9FBAAC16-13D8-4FAE-BEE9-34F6D167E037Q33688908-3A11C05C-D7D5-4892-BAC3-1DBE579E188BQ33761278-03C1C6B6-B027-449A-9309-3D6568610614Q33806121-E15A72FE-951E-4E79-BC13-2F840DDEB629Q33860323-638B04CE-2586-436C-A8D6-3F4E1FC4390EQ33891730-5D80D8C0-910E-49BD-B1E1-CA288A194646Q33891755-2D8DBC09-B68E-4F81-8765-D6D00F7D6BA8Q33985467-DBB11DEB-6DA4-484A-AF36-39382884A29EQ33996931-9DEE7DBD-FAB4-48EA-82EF-285CFFA46B24Q34011801-8FE3AE0A-09B9-4A6E-A169-C017811BD947Q34048053-F2A2C862-FAB0-4016-A8BD-44D77BB52406Q34487603-E3959A05-9B5A-4764-82BA-3BACFE812311Q34497217-F08C17CB-0401-4E1A-B510-A699619E96F5Q34610933-6C9B08DB-1B6B-424C-8F0F-BD62D2D27F49Q34635688-4B93208A-ACFA-42FA-B07E-7A1C98ED5A4C
P2860
Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Everolimus for the prevention ...... cardiac-transplant recipients.
@ast
Everolimus for the prevention ...... cardiac-transplant recipients.
@en
type
label
Everolimus for the prevention ...... cardiac-transplant recipients.
@ast
Everolimus for the prevention ...... cardiac-transplant recipients.
@en
prefLabel
Everolimus for the prevention ...... cardiac-transplant recipients.
@ast
Everolimus for the prevention ...... cardiac-transplant recipients.
@en
P2093
P356
P1476
Everolimus for the prevention ...... cardiac-transplant recipients.
@en
P2093
Donna Mancini
E Murat Tuzcu
Hannah A Valantine-von Kaeppler
Howard J Eisen
Joan M Lind
Jon Kobashigawa
Kamal H Abeywickrama
Keld Sørensen
Manfred Hummel
Peter Bernhardt
P304
P356
10.1056/NEJMOA022171
P407
P577
2003-08-01T00:00:00Z